Stock Mover of the Day: Global Blood Therapeutics Inc’s Trend Down, Especially After Today’s Weak Session

Stock Mover of the Day: Global Blood Therapeutics Inc's Trend Down, Especially After Today's Weak Session

The stock of Global Blood Therapeutics Inc (NASDAQ:GBT) is a huge mover today! The stock decreased 3.25% or $0.75 during the last trading session, hitting $22.3. About 415,564 shares traded hands. Global Blood Therapeutics Inc (NASDAQ:GBT) has risen 48.57% since March 1, 2016 and is uptrending. It has outperformed by 36.35% the S&P500.
The move comes after 7 months negative chart setup for the $936.72M company. It was reported on Oct, 4 by Barchart.com. We have $20.74 PT which if reached, will make NASDAQ:GBT worth $65.57M less.

Analysts await Global Blood Therapeutics Inc (NASDAQ:GBT) to report earnings on November, 10. They expect $-0.59 earnings per share, up 34.44% or $0.31 from last year’s $-0.9 per share. After $-0.58 actual earnings per share reported by Global Blood Therapeutics Inc for the previous quarter, Wall Street now forecasts 1.72% negative EPS growth.

Global Blood Therapeutics Inc (NASDAQ:GBT) Ratings Coverage

Out of 4 analysts covering Global Blood Therapeutics (NASDAQ:GBT), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Global Blood Therapeutics has been the topic of 6 analyst reports since September 8, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Friday, June 17 by Empire. On Tuesday, September 8 the stock rating was initiated by Cowen & Co with “Outperform”. Morgan Stanley initiated the stock with “Overweight” rating in Tuesday, September 8 report. The stock of Global Blood Therapeutics Inc (NASDAQ:GBT) earned “Outperform” rating by Wedbush on Tuesday, September 8. The stock of Global Blood Therapeutics Inc (NASDAQ:GBT) has “Neutral” rating given on Tuesday, September 8 by Goldman Sachs.

According to Zacks Investment Research, “Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California.”

More notable recent Global Blood Therapeutics Inc (NASDAQ:GBT) news were published by: Fool.com which released: “Why Global Blood Therapeutics Inc Shares Are Tanking Today” on December 07, 2015, also Marketwatch.com with their article: “Global Blood Therapeutics shares jump after positive results for pivotal drug” published on June 10, 2016, Benzinga.com published: “Global Blood Therapeutics Shares Spiking On Analyst’s Positive Outlook” on September 30, 2016. More interesting news about Global Blood Therapeutics Inc (NASDAQ:GBT) were released by: Prnewswire.com and their article: “Global Blood Therapeutics Announces Appointment of Jeffrey Farrow as CFO” published on April 04, 2016 as well as Prnewswire.com‘s news article titled: “Global Blood Therapeutics Reports Recent Business Progress and Provides First …” with publication date: May 12, 2016.

GBT Company Profile

Global Blood Therapeutics, Inc., incorporated on February 04, 2011, is a clinical-stage biopharmaceutical company. The Firm is engaged in discovering, developing and commercializing therapeutics to treat blood disorders. The Company’s segment is engaged in discovering, developing and commercializing therapeutics to treat blood disorders. The Firm is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD) and is evaluating GBT440 in SCD subjects in an ongoing Phase I/II clinical trial. SCD is a genetic disease marked by red blood cell (RBC) destruction and occluded blood flow and hypoxia, leading to anemia, stroke, multi-organ failure, severe pain crises, and shortened patient life span. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Firm is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). HAE is a rare, genetic disorder characterized by severe and potentially life-threatening systemic inflammation.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment